Expert Insight on Key Updates and New Clinical Trial Data From the ESGO 2023 Congress Informing Treatment for Cervical, Ovarian, and Endometrial Cancers

In this episode, Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, provide expert insights on key updates and new clinical trial data presented at the ESGO 2023 Congress for cervical, endometrial, and ovarian cancers, including:

• Long-Term Follow Up From Phase III SIENDO Study of Selinexor vs Pbo Maintenance in Patients With TP53wt Advanced/Recurrent Endometrial Cancer 
• Global, Open-Label, Phase I/IIa of HER2-Targeting ADC (DB-1303) in Recurrent/Metastatic Endometrial Cancer
• Phase III From KEYNOTE-826: Bevacizumab Subgroup Analysis Based on Protocol Specified Final Overall Survival Results
• Phase III ICON8B: Weekly DD-CT + Bev vs Q3W CT + Bev as First Line in High-Risk Epithelial Ovarian Cancer
• HRD Testing on Cell-Free Tumor DNA From Peritoneal Fluid of Patients With Newly-Diagnosed Epithelial Ovarian Cancer

Presenters:

Alexandra Leary, MD, PhD
Co Director
Medical Oncologist and Team Leader
Gynecology Translational Research Lab
Department of Medicine
Gustave Roussy Cancer Center
Paris, France

Domenica Lorusso, MD, PhD
Associate Professor
Gynecologic Oncology Department
Clinical Research Unit
Fondazione Policlinico Gemelli IRCCS
Rome, Italy

This educational activity is supported by educational grants from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme Corp, Novocure, Genmab, and Seagen. 

Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries:
https://bit.ly/424E3Uq

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.